Health Care·Biotechnology·$2.2B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.22 | N/A | +9.47% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.22 | N/A | +9.47% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management expressed cautious optimism about future prospects. They noted progress in product development but did not provide specific guidance.
Management highlighted ongoing developments in their pipeline.
They emphasized the importance of upcoming clinical trials.
Biocryst Pharmaceuticals reported a smaller-than-expected loss per share, which was a positive surprise for investors. However, the stock still declined by 0.74%, likely due to a lack of revenue information and no updated guidance. Investors may be cautious as the company did not provide specific future expectations.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
AMKOR TECHNOLOGY INC
Aug 1, 2016